increased 14.50% last quarter as well. The number of holdings in the portfolio remained steady at 18: Take-Two Interactive Software position was eliminated and Hologic Inc. was newly added during the quarter. The Complete Story »
Hologic reported first-quarter earnings on Monday ..... necessary step toward broadening the appeal of Hologic 's equipment. Adjusted gross margins ..... Despite an uptick in administrative costs, Hologic kept overall operating expenses in check
Hologic , Inc. ( HOLX ) F1Q 2014 Earnings Conference Call February 3, 2014 17:00 ET Executives ..... Craig-Hallum Presentation Operator Good afternoon, and welcome to the Hologic Incorporated First Quarter Fiscal 2014 Earnings Conference Call. My
Feb 3 (Reuters) - Medical device maker Hologic Inc reported a better-than-expected adjusted quarterly profit as it sold more 3D systems that help detect breast cancer, and its CEO said he would pursue the strategic review started by his predecessor.
Hologic ( HOLX ) expects FQ2 revenue of $605M-$615M; the $610M midpoint is favorable ..... but G&A spend rose 25% to $67.8M. CEO Stephen MacMillan says Hologic will be focused on improving its "operating performance and growth profile
Feb 3 (Reuters) - Medical device maker Hologic Inc reported a better-than-expected adjusted quarterly profit, helped by higher sales of its 3D digital mammography systems.
Hologic , Inc. ( HOLX ): FQ1 EPS of $0.34 beats by $0.03 . Revenue of $612.4M (-5.0% Y/Y) beats by $2.75M . Shares +2.6% . Press Release Post your comment!
ADVS , AEIS , AFOP , AGNC , APC , APU , ARE , BRE , CCK , CFN , DNB , EW , GGP , HIG , HOLX , IDTI , LMNX , MDU , OHI , PFG , PRE , PSMI , SU , TMK , TTWO , UGI , YUM Post your comment!
ADVS , AEIS , AFOP , AGNC , APC , APU , ARE , BRE , CCK , CFN , DNB , EW , GGP , HIG , HOLX , IDTI , LMNX , MDU , OHI , PFG , PRE , PSMI , SU , TMK , TTWO , UGI , YUM 1 comment!
general, and administrative leverage as Alere integrates acquired businesses. Lastly, recent M&A activity in diagnostics-- Hologic 's acquisition of Gen-Probe, Roche's attempted takeover of Illumina--could be an impetus for other companies to pursue